IGC Stock Forecast 2025-2026
Distance to IGC Price Targets
IGC Price Momentum
🤔 Considering India Globalization Capital (IGC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest IGC Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, IGC has a bullish consensus with a median price target of $3.88 (ranging from $3.50 to $4.25). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.33, the median forecast implies a 1,057.4% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 1,169.4% upside. Conversely, the most conservative target is provided by James Molloy at Alliance Global Partners, suggesting a 945.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IGC Analyst Ratings
IGC Price Target Range
Latest IGC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IGC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2025 | Alliance Global Partners | James Molloy | Buy | Reiterates | $3.50 |
| Feb 24, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $4.25 |
| Dec 5, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $4.00 |
| Sep 3, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $3.75 |
| Jul 29, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $3.50 |
| Jul 17, 2024 | Alliance Global Partners | James Molloy | Buy | Initiates | $3.50 |
| Jun 21, 2024 | Ascendiant Capital | Edward Woo | Buy | Reiterates | $3.25 |
IGC Pharma Inc. (IGC) Competitors
The following stocks are similar to India Globalization Capital based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IGC Pharma Inc. (IGC) Financial Data
IGC Pharma Inc. has a market capitalization of $26.68M with a P/E ratio of -1.5x. The company generates $1.24M in trailing twelve-month revenue with a 54.5% profit margin.
Revenue growth is +26.0% quarter-over-quarter, while maintaining an operating margin of -730.7% and return on equity of -115.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
IGC Pharma Inc. (IGC) Business Model
About IGC Pharma Inc.
Develops innovative therapies for chronic pain and cancer.
IGC Pharma Inc. generates revenue through the research, development, and commercialization of novel therapies targeting chronic pain, cancer, and other serious conditions. The company focuses on leveraging cannabinoids in its drug development processes, aiming to meet significant unmet medical needs in the pharmaceutical market.
Operating in the biotech sector, IGC Pharma is engaged in extensive R&D with a robust pipeline of products at various clinical trial stages. Its strategic integration of traditional pharma methods with cannabinoid advancements positions it as a potential leader in pain management and oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
67
CEO
Mr. Ram Mukunda
Country
United States
IPO Year
2006
Website
igcpharma.comIGC Pharma Inc. (IGC) Latest News & Analysis
IGC Pharma, Inc. (NYSE American: IGC) announced a coverage report from Ascendiant Capital Markets highlighting expectations for positive clinical data in 2025 as a catalyst for its stock.
IGC Pharma's positive Q3 results and anticipated favorable clinical data in 2025 could boost investor confidence and drive stock performance.
IGC Pharma (NYSE American: IGC) announced that Alliance Global Partners released a report on its Alzheimer-targeting efforts, highlighting positive interim results from Phase 2 CALMA.
IGC Pharma's positive Phase 2 CALMA results could indicate potential growth in value, attracting investor interest in the company's Alzheimer-targeting initiatives.
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
11 days agoIGC Pharma, Inc. announced the development of a new AI model aimed at improving Alzheimer's disease diagnosis, which is crucial for effective treatment strategies in dementia cases.
IGC Pharma's AI advancement for Alzheimer's diagnosis could enhance treatment accuracy and market potential, signaling growth opportunities and innovation in a crucial healthcare sector.
IGC Pharma, Inc. reported its Q3 2025 financial results, highlighting advancements in its Phase 2 CALMA trial for IGC-AD1, targeting agitation in Alzheimer's patients.
IGC Pharma's progress in its Phase 2 CALMA trial for Alzheimer's could impact its stock value, reflecting potential growth in a high-demand healthcare sector.
IGC Pharma is launching two new product lines, Longevity and Renew, under its Holiby™ brand, focusing on anti-aging and cellular health. The company will enhance its e-commerce and marketing strategies.
IGC Pharma's launch of new wellness products taps into growing demand for anti-aging solutions, potentially boosting revenue and market share through innovative marketing strategies.
IGC Pharma, Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of $0.03, and an improvement from a loss of $0.09 per share a year earlier.
IGC's smaller-than-expected loss signals potential improvement in financial performance, which may boost investor confidence and influence stock valuation.
Frequently Asked Questions About IGC Stock
What is IGC Pharma Inc.'s (IGC) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, IGC Pharma Inc. (IGC) has a median price target of $3.88. The highest price target is $4.25 and the lowest is $3.50.
Is IGC stock a good investment in 2025?
According to current analyst ratings, IGC has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IGC stock?
Wall Street analysts predict IGC stock could reach $3.88 in the next 12 months. This represents a 1,057.4% increase from the current price of $0.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IGC Pharma Inc.'s business model?
IGC Pharma Inc. generates revenue through the research, development, and commercialization of novel therapies targeting chronic pain, cancer, and other serious conditions. The company focuses on leveraging cannabinoids in its drug development processes, aiming to meet significant unmet medical needs in the pharmaceutical market.
What is the highest forecasted price for IGC IGC Pharma Inc.?
The highest price target for IGC is $4.25 from Edward Woo at Ascendiant Capital, which represents a 1,169.4% increase from the current price of $0.33.
What is the lowest forecasted price for IGC IGC Pharma Inc.?
The lowest price target for IGC is $3.50 from James Molloy at Alliance Global Partners, which represents a 945.4% increase from the current price of $0.33.
What is the overall IGC consensus from analysts for IGC Pharma Inc.?
The overall analyst consensus for IGC is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.88.
How accurate are IGC stock price projections?
Stock price projections, including those for IGC Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
